Shifamed‘s Adona Medical announced today that it completed enrollment in the ATHENS-HF first-in-human study of its ...

Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced today the successful first-in-human use of its novel interatrial shunt in patients ...

The funds will allow Corvia to accumulate the final clinical data required to support a submission for the system with the ...

Objectives: Recently introduced paediatric cardiac output monitor (COstatus, Transonic Systems Inc. Ithaca, NY) also measures blood volumes and detects cardiac shunts. The current study assessed ...

Inter-atrial shunts are small (5-10 millimeter diameter) permanent devices, placed in the heart via a minimally invasive catheter-based procedure, that connect the left and right atria.

Patients with heart failure who had a small shunt inserted between the heart's left and right atria did not see any significant benefits overall compared with those who received a placebo ...

Duration of Heart Failure, Cardiac Dysfunction and Remodeling, and Response to Atrial Shunt Treatment in HFpEF and HFmrEF. Presenter: Barry Borlaug. February 11, 2025. ... Insights From ...

Interatrial shunt implant lowered HF hospitalization risk for patients with HFrEF vs. placebo. However, patients with HFpEF had more than threefold increased risk for all-cause mortality ...

Adona Medical, a Shifamed portfolio company that is developing one of the world's first combined therapeutic/diagnostic ...